Literature DB >> 28404191

Tackling cancers of unmet need: the pancreatic cancer pathway.

Sara Macdonald1, Frances Mair2.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 28404191     DOI: 10.1016/S2468-1253(16)30113-3

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


× No keyword cloud information.
  1 in total

1.  Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.

Authors:  Davide Melisi; Do-Youn Oh; Antoine Hollebecque; Emiliano Calvo; Anna Varghese; Erkut Borazanci; Teresa Macarulla; Valeria Merz; Camilla Zecchetto; Yumin Zhao; Ivelina Gueorguieva; Michael Man; Leena Gandhi; Shawn T Estrem; Karim A Benhadji; Mark C Lanasa; Emin Avsar; Susan C Guba; Rocio Garcia-Carbonero
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.